Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Active Biotech ABFRA:BTP +0.86%30 Earnings per Share (Diluted) is €-0.13 as of Jun. 2026. GuruFocus rates FRA:BTP with a GF Score™ of 30/100 and a GF Value™ of €0.13 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Active Biotech AB ranks better than 64.22% on this metric.
Active Biotech AB's EPS (Basic) for the
three
months ended in Jun. 2026 was €-0.04.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.13.
During the past 3 years, the average EPS without NRIGrowth Rate was 27.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 10.20% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 14.40% per year.
During the past 13 years, Active Biotech AB's highest 3-Year average EPS without NRI Growth Rate was 45.40% per year. The lowest was -29.10% per year. And the median was 5.30% per year.
Active Biotech AB (FRA:BTP) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Active Biotech AB Earnings per Share (Diluted) Related Terms
Active Biotech AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Active Biotech AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Active Biotech AB Earnings per Share (Diluted) Chart
FRA:BTP vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Active Biotech AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Active Biotech AB PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Active Biotech AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Active Biotech AB's PE Ratio falls into.
Active Biotech AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Active Biotech AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €-0.13 mean?
Active Biotech AB (FRA:BTP) has a Earnings per Share (Diluted) of €-0.13 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Active Biotech AB and its competitors. According to the industry distribution chart, Active Biotech AB ranks #415 out of 1160 companies in the Biotechnology industry, placing it in the top 35.8%.
Is Active Biotech AB's Earnings per Share (Diluted) too high?
Active Biotech AB's current Earnings per Share (Diluted) is €-0.13. Based on the distribution chart, Active Biotech AB ranks #415 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Active Biotech AB has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Active Biotech AB's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Active Biotech AB ranks #415 out of 1160 companies for Earnings per Share (Diluted). This puts Active Biotech AB in the upper half of its industry. The industry median Earnings per Share (Diluted) is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Active Biotech AB and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Active Biotech AB's current Earnings per Share (Diluted) is €-0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Active Biotech AB stock overvalued right now?
Based on GuruFocus' analysis, Active Biotech AB (FRA:BTP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.13, compared to a current price of €0.41 — trading 214.2% above its estimated fair value. The current Earnings per Share (Diluted) is €-0.13. Active Biotech AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Active Biotech AB (FRA:BTP), the current Earnings per Share (Diluted) is €-0.13 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Active Biotech AB (FRA:BTP) Overvalued in 2026?
Based on GuruFocus' analysis, Active Biotech AB stock appears to be overvalued.
The current stock price of €0.41 is trading 214.2% above its estimated GF Value™ of €0.13.
GuruFocus considers Active Biotech AB to be Significantly Overvalued.
Key valuation signals for FRA:BTP:
Earnings per Share (Diluted): €-0.13
GF Value™: €0.13 vs. price of €0.41 (214.2% above fair value)
No single metric tells the full story. See the FRA:BTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Active Biotech AB focuses on the research and development of pharmaceuticals products within medical areas including neurodegenerative diseases, autoimmune/inflammatory disease and various forms of cancer. Its project portfolio contains both small molecules that are orally active immunomodulatory agents and antibody based immunotherapy. Its project portfolio includes both small orally active immunomodulatory molecules and antibody-based immunotherapy. Its pipeline products are: Tasquinimod, Laquinimod, and Naptumomab.
30GF Score
Get the complete analysis for FRA:BTP
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BTP has been successfully added to your 
